Pro-inflammatory and antiviral cytokine expression in vaccinated and unvaccinated horses exposed to equine influenza virus

Vaccine

Volumn 25, Issue 41, 2007, Pages 7056-7064

  Quinlivan, Michelle ^a,d   Nelly, Maura ^a   Prendergast, Michael ^b   Breathnach, Cormac ^c   Horohov, David ^c   Arkins, Sean ^d   Chiang, Yu Wei ^e   Chu, Hsien Jue ^e   Ng, Terry ^e   Cullinane, Ann ^a  

^a IRISH EQUINE CENTRE   (Ireland)

^b Ash Stream Ltd   (Ireland)

^c UNIVERSITY OF KENTUCKY   (United States)

^d UNIVERSITY OF LIMERICK   (Ireland)

^e ZOETIS   (United States)

Author keywords

Cytokine; Equine influenza; qPCR

Indexed keywords

ALPHA INTERFERON; CYTOKINE; DUVAXYN; HUMORAL ANTIBODY; INFLUENZA VACCINE; INTERLEUKIN 1BETA; INTERLEUKIN 6; MESSENGER RNA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; FEMALE; GENE EXPRESSION; HORSE; INFLAMMATION; INFLUENZA; INFLUENZA VIRUS; MALE; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VACCINATION; VIRUS SHEDDING;

ANIMALS; ANTIBODIES, VIRAL; CYTOKINES; FEMALE; HORSE DISEASES; HORSES; IMMUNODIFFUSION; INFLUENZA A VIRUS, H3N8 SUBTYPE; INFLUENZA VACCINES; MALE; ORTHOMYXOVIRIDAE INFECTIONS; RANDOM ALLOCATION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SEVERITY OF ILLNESS INDEX; VACCINES, INACTIVATED; VIRUS SHEDDING;

EID: 34648828883     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2007.07.059     Document Type: Article

References (61)

1. Sovinova O., Tumova B., Pouska F., and Nemec J. Isolation of a virus causing respiratory disease in horses. Acta Virol 2 1 (1958) 52-61
2. Waddell G.H., Teigland M.B., and Sigel M.M. A new influenza virus associated with equine respiratory disease. J Am Vet Med Assoc 143 (1963) 587-590
3. Webster R.G. Are equine 1 influenza viruses still present in horses?. Equine Vet J 25 6 (1993) 537-538
4. Mumford E.L., Traub-Dargatz J.L., Salman M.D., Collins J.K., Getzy D.M., and Carman J. Monitoring and detection of acute viral respiratory tract disease in horses. J Am Vet Med Assoc 213 3 (1998) 385-390
5. Newton J.R., Townsend H.G., Wood J.L., Sinclair R., Hannant D., and Mumford J.A. Immunity to equine influenza: relationship of vaccine-induced antibody in young thoroughbred racehorses to protection against field infection with influenza A/equine-2 viruses (H3N8). Equine Vet J 32 1 (2000) 65-74
6. Hannant D., Mumford J.A., and Jessett D.M. Duration of circulating antibody and immunity following infection with equine influenza virus. Vet Rec 122 6 (1988) 125-128
7. Nelson K.M., Schram B.R., McGregor M.W., Sheoran A.S., Olsen C.W., and Lunn D.P. Local and systemic isotype-specific antibody responses to equine influenza virus infection versus conventional vaccination. Vaccine 16 13 (1998) 1306-1313
8. Wilson W.D., Mihalyi J.E., Hussey S., and Lunn D.P. Passive transfer of maternal immunoglobulin isotype antibodies against tetanus and influenza and their effect on the response of foals to vaccination. Equine Vet J 33 7 (2001) 644-650
9. Lunn D.P., Soboll G., Schram B.R., Quass J., McGregor M.W., Drape R.J., et al. Antibody responses to DNA vaccination of horses using the influenza virus hemagglutinin gene. Vaccine 17 18 (1999) 2245-2258
10. Hannant D., Jessett D.M., O'Neill T., and Mumford J.A. Antibody isotype responses in the serum and respiratory tract to primary and secondary infections with equine influenza virus (H3N8). Vet Microbiol 19 4 (1989) 293-303
11. Julkunen I., Sareneva T., Pirhonen J., Ronni T., Melen K., and Matikainen S. Molecular pathogenesis of influenza A virus infection and virus-induced regulation of cytokine gene expression. Cytokine Growth Factor Rev 12 2-3 (2001) 171-180
12. Ronni T., Sareneva T., Pirhonen J., and Julkunen I. Activation of IFN-alpha, IFN-gamma, MxA, and IFN regulatory factor 1 genes in influenza A virus-infected human peripheral blood mononuclear cells. J Immunol 154 6 (1995) 2764-2774
13. Pavlovic J., Haller O., and Staeheli P. Human and mouse Mx proteins inhibit different steps of the influenza virus multiplication cycle. J Virol 66 4 (1992) 2564-2569
14. Stark G.R., Kerr I.M., Williams B.R., Silverman R.H., and Schreiber R.D. How cells respond to interferons. Annu Rev Biochem 67 (1998) 227-264
15. Biron C.A. Interferons alpha and beta as immune regulators-a new look. Immunity 14 6 (2001) 661-664
16. Le Bon A., Schiavoni G., D'Agostino G., Gresser I., Belardelli F., and Tough D.F. Type I interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo. Immunity 14 4 (2001) 461-470
17. Boraschi D., Bossu P., Macchia G., Ruggiero P., and Tagliabue A. Structure-function relationship in the IL-1 family. Front Biosci 1 (1996) d270-d308
18. Simpson R.J., Hammacher A., Smith D.K., Matthews J.M., and Ward L.D. Interleukin-6: structure-function relationships. Protein Sci 6 5 (1997) 929-955
19. Ramsay A.J., Husband A.J., Ramshaw I.A., Bao S., Matthaei K.I., Koehler G., et al. The role of interleukin-6 in mucosal IgA antibody responses in vivo. Science 264 5158 (1994) 561-563
20. Van Reeth K. Cytokines in the pathogenesis of influenza. Vet Microbiol 74 1-2 (2000) 109-116
21. Seo S.H., and Webster R.G. Tumor necrosis factor alpha exerts powerful anti-influenza virus effects in lung epithelial cells. J Virol 76 3 (2002) 1071-1076
22. Kaufmann A., Salentin R., Meyer R.G., Bussfeld D., Pauligk C., Fesq H., et al. Defense against influenza A virus infection: essential role of the chemokine system. Immunobiology 204 5 (2001) 603-613
23. Wattrang E., Jessett D.M., Yates P., Fuxler L., and Hannant D. Experimental infection of ponies with equine influenza A2 (H3N8) virus strains of different pathogenicity elicits varying interferon and interleukin-6 responses. Viral Immunol 16 1 (2003) 57-67
24. Hulten C., Sandgren B., Skioldebrand E., Klingeborn B., Marhaug G., and Forsberg M. The acute phase protein serum amyloid A (SAA) as an inflammatory marker in equine influenza virus infection. Acta Vet Scand 40 4 (1999) 323-333
25. Soboll G., Horohov D.W., Aldridge B.M., Olsen C.W., McGregor M.W., Drape R.J., et al. Regional antibody and cellular immune responses to equine influenza virus infection, and particle mediated DNA vaccination. Vet Immunol Immunopathol 94 1-2 (2003) 47-62
26. Hartel C., Bein G., Muller-Steinhardt M., and Kluter H. Ex vivo induction of cytokine mRNA expression in human blood samples. J Immunol Methods 249 1-2 (2001) 63-71
27. Rainen L., Oelmueller U., Jurgensen S., Wyrich R., Ballas C., Schram J., et al. Stabilization of mRNA expression in whole blood samples. Clin Chem 48 11 (2002) 1883-1890
28. Nelly M. Characterisation of equine influenza virus isolates from the 1989 and 1992 influenza outbreaks in Ireland by nucleotide sequence determination of the haemagglutinin molecule, M.Sc. Thesis; 1996.
29. Mumford J.A., Hannant D., and Jessett D.M. Experimental infection of ponies with equine influenza (H3N8) viruses by intranasal inoculation or exposure to aerosols. Equine Vet J 22 2 (1990) 93-98
30. Wood J.M., Mumford J., Folkers C., Scott A.M., and Schild G.C. Studies with inactivated equine influenza vaccine. 1: Serological responses of ponies to graded doses of vaccine. J Hyg (Lond) 90 3 (1983) 371-384
31. Quinlivan M., Dempsey E., Ryan F., Arkins S., and Cullinane A. Real-time reverse transcription PCR for detection and quantitative analysis of equine influenza virus. J Clin Microbiol 43 10 (2005) 5055-5057
32. Fouchier R.A., Bestebroer T.M., Herfst S., Van Der Kemp L., Rimmelzwaan G.F., and Osterhaus A.D. Detection of influenza A viruses from different species by PCR amplification of conserved sequences in the matrix gene. J Clin Microbiol 38 11 (2000) 4096-4101
33. Quinlivan M., Cullinane A., Nelly M., Van Maanen K., Heldens J., and Arkins S. Comparison of sensitivities of virus isolation, antigen detection, and nucleic acid amplification for detection of equine influenza virus. J Clin Microbiol 42 2 (2004) 759-763
34. Livak K.J., and Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25 4 (2001) 402-408
35. Dheda K., Huggett J.F., Bustin S.A., Johnson M.A., Rook G., and Zumla A. Validation of housekeeping genes for normalizing RNA expression in real-time PCR. Biotechniques 37 1 (2004) 112-114 116, 118-9
36. Shipley J.M., Miller R.D., Wu B.M., Grubb J.H., Christensen S.G., Kyle J.W., et al. Analysis of the 5′ flanking region of the human beta-glucuronidase gene. Genomics 10 4 (1991) 1009-1018
37. Aerts J.L., Gonzales M.I., and Topalian S.L. Selection of appropriate control genes to assess expression of tumor antigens using real-time RT-PCR. Biotechniques 36 1 (2004) 84-86 88, 90-1
38. Bustin S.A. Absolute quantification of mRNA using real-time reverse transcription polymerase chain reaction assays. J Mol Endocrinol 25 2 (2000) 169-193
39. Mumford J.A., and Wood J. Establishing an acceptability threshold for equine influenza vaccines. Dev Biol Stand 79 (1992) 137-146
40. Ginzinger D.G. Gene quantification using real-time quantitative PCR: an emerging technology hits the mainstream. Exp Hematol 30 6 (2002) 503-512
41. Blaschke V., Reich K., Blaschke S., Zipprich S., and Neumann C. Rapid detection of proinflammatory and chemoattractant cytokine expression in small tissue samples and monocyte-derived dendritic cells: validation of a new real-time RT-PCR technology. J Immunol Methods 246 1-2 (2000) 79-90
42. Breathnach C.C., Rudersdorf R., and Lunn D.P. Use of recombinant modified vaccinia Ankara viral vectors for equine influenza vaccination. Vet Immunol Immunopathol 98 3-4 (2004) 127-136
43. Giulietti A., Overbergh L., Valckx D., Decallonne B., Bouillon R., and Mathieu C. An overview of real-time quantitative PCR: applications to quantify cytokine gene expression. Methods 25 4 (2001) 386-401
44. Stordeur P., Zhou L., Byl B., Brohet F., Burny W., de Groote D., et al. Immune monitoring in whole blood using real-time PCR. J Immunol Methods 276 1-2 (2003) 69-77
45. Swiderski C.E., Klei T.R., and Horohov D.E. Quantitative measurement of equine cytokine mRNA expression by polymerase chain reaction using target-specific standard curves. J Immunol Methods 222 1-2 (1999) 155-169
46. Yin J.L., Shackel N.A., Zekry A., McGuinness P.H., Richards C., Putten K.V., et al. Real-time reverse transcriptase-polymerase chain reaction (RT-PCR) for measurement of cytokine and growth factor mRNA expression with fluorogenic probes or SYBR Green I. Immunol Cell Biol 79 3 (2001) 213-221
47. Sareneva T., Matikainen S., Kurimoto M., and Julkunen I. Influenza A virus-induced IFN-alpha/beta and IL-18 synergistically enhance IFN-gamma gene expression in human T cells. J Immunol 160 12 (1998) 6032-6038
48. Murphy B.R., Baron S., Chalhub E.G., Uhlendorf C.P., and Chanock R.M. Temperature-sensitive mutants of influenza virus. IV: Induction of interferon in the nasopharynx by wild-type and a temperature-sensitive recombinant virus. J Infect Dis 128 4 (1973) 488-493
49. Hayden F.G., Fritz R.S., Lobo M.C., Alvord W.G., Strober W., and Straus E. Local and systemic cytokine responses during experimental human influenza A virus infection. J Clin Invest 101 3 (1998) 643-649
50. Aderka D., Le J., and Vilcek J. IL-6 inhibits lipopolysaccharide-induced tumor necrosis factor production in cultured human monocytes, U937 cells and in mice. J Immunol 143 11 (1989) 3517-3523
51. Vacheron F., Rudent A., Perin S., Labarre C., Quero A.M., and Guenounou M. Production of interleukin 1 and tumour necrosis factor activities in bronchoalveolar washings following infection of mice by influenza virus. J Gen Virol 71 Pt 2 (1990) 477-479
52. Van Reeth K., Nauwynck H., and Pensaert M. Bronchoalveolar interferon-alpha, tumor necrosis factor-alpha, interleukin-1, and inflammation during acute influenza in pigs: a possible model for humans?. J Infect Dis 177 4 (1998) 1076-1079
53. Riches P., Gooding R., Millar B.C., and Rowbottom A.W. Influence of collection and separation of blood samples on plasma IL-1, IL-6 and TNF-alpha concentrations. J Immunol Methods 153 1-2 (1992) 125-131
54. Tanner M.A., Berk L.S., Felten D.L., Blidy A.D., Bit S.L., and Ruff D.W. Substantial changes in gene expression level due to the storage temperature and storage duration of human whole blood. Clin Lab Haematol 24 6 (2002) 337-341
55. Chai V., Vassilakos A., Lee Y., Wright J.A., and Young A.H. Optimization of the PAXgene blood RNA extraction system for gene expression analysis of clinical samples. J Clin Lab Anal 19 5 (2005) 182-188
56. Muller M.C., Hordt T., Paschka P., Merx K., La Rosee P., Hehlmann R., et al. Standardization of preanalytical factors for minimal residual disease analysis in chronic myelogenous leukemia. Acta Haematol 112 1-2 (2004) 30-33
57. Isaksson H.S., and Nilsson T.K. Preanalytical aspects of quantitative TaqMan real-time RT-PCR: applications for TF and VEGF mRNA quantification. Clin Biochem 39 4 (2006) 373-377
58. Wang J., Robinson J.F., Khan H.M., Carter D.E., McKinney J., Miskie B.A., et al. Optimizing RNA extraction yield from whole blood for microarray gene expression analysis. Clin Biochem 37 9 (2004) 741-744
59. Thach D.C., Lin B., Walter E., Kruzelock R., Rowley R.K., Tibbetts C., et al. Assessment of two methods for handling blood in collection tubes with RNA stabilizing agent for surveillance of gene expression profiles with high density microarrays. J Immunol Methods 283 1-2 (2003) 269-279
60. Prezeau N., Silvy M., Gabert J., and Picard C. Assessment of a new RNA stabilizing reagent (Tempus Blood RNA) for minimal residual disease in onco-hematology using the EAC protocol. Leuk Res 30 5 (2006) 569-574
61. Heid C.A., Stevens J., Livak K.J., and Williams P.M. Real time quantitative PCR. Genome Res 6 10 (1996) 986-994